Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
Holders of 5% or more of STOK
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Stoke Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G | 10.70%5.86M shares | New | Jun 6, 20251 filing | Jun 6, 2025 | SEC |
| RTW Investments, LP | 13G/A | 9.99%5.31M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Morgan Stanley | 13G/A | 6.50%3.43M shares | – | Feb 3, 20251 filing | Feb 3, 2025 | SEC |
| Skorpios Trust | 13D/A | 6.00%3.26M shares | −1.20 ppfrom 7.20% | Dec 27, 20243 filings | Jun 23, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 5.80%3.12M shares | – | Apr 16, 20251 filing | Apr 16, 2025 | SEC |
| BlackRock Portfolio Management LLC | 13G | 5.10%2.74M shares | New | Apr 15, 20251 filing | Apr 15, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
8 Schedule 13D and 13G filings on Stoke Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 23, 20254:47 PM ET | Skorpios Trustand 3 others | 13D/A | 6.00%3.26M shares | −1.20 ppfrom 7.20% | Jun 18, 2025 | SEC |
| Jun 6, 20254:23 PM ET | Skorpios Trustand 3 others | 13D/A | 7.20%3.91M shares | −5.80 ppfrom 13.00% | Jun 4, 2025 | SEC |
| Jun 6, 202510:03 AM ET | FMR LLCand 1 other | 13G | 10.70%5.86M shares | New | May 30, 2025 | SEC |
| Apr 16, 20256:41 PM ET | BlackRock, Inc. | 13G/A | 5.80%3.12M shares | – | Mar 31, 2025 | SEC |
| Apr 15, 20255:04 PM ET | BlackRock Portfolio Management LLC | 13G | 5.10%2.74M shares | New | Mar 31, 2025 | SEC |
| Feb 14, 20259:00 AM ET | RTW Investments, LPand 1 other | 13G/A | 9.99%5.31M shares | – | Dec 31, 2024 | SEC |
| Feb 3, 20254:36 PM ET | Morgan Stanleyand 1 other | 13G/A | 6.50%3.43M shares | – | Dec 31, 2024 | SEC |
| Dec 27, 20245:23 PM ET | Skorpios Trustand 3 others | 13D/A | 13.00%6.91M shares | – | Dec 23, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Stoke Therapeutics, Inc. shares.
No Form 144 notices for Stoke Therapeutics, Inc. are on file.